$127 Million is the total value of Prosight Management, LP's 24 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GLPG | Sell | GALAPAGOS NVspon adr | $20,590,000 | -11.2% | 369,000 | -1.3% | 16.22% | +8.3% |
| PRTA | Sell | PROTHENA CORP PLC | $14,933,000 | -27.9% | 550,000 | -2.9% | 11.77% | -12.0% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $10,442,000 | +109.4% | 1,262,691 | +320.9% | 8.23% | +155.5% |
| ALBO | Sell | ALBIREO PHARMA INC | $9,290,000 | -35.1% | 467,795 | -2.5% | 7.32% | -20.8% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $8,076,000 | -7.0% | 820,752 | +39.3% | 6.36% | +13.5% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $7,924,000 | +27.3% | 1,985,883 | +41.8% | 6.24% | +55.4% |
| MGTX | Buy | MEIRAGTX HLDGS PLC | $7,466,000 | +41.6% | 986,218 | +159.1% | 5.88% | +72.8% |
| CRL | Sell | CHARLES RIV LABS INTL INC | $5,884,000 | -34.2% | 27,500 | -12.7% | 4.64% | -19.7% |
| ONEM | New | 1LIFE HEALTHCARE INC | $5,684,000 | – | 725,000 | +100.0% | 4.48% | – |
| New | QUIDELORTHO CORP | $4,526,000 | – | 46,576 | +100.0% | 3.57% | – | |
| STTK | Buy | SHATTUCK LABS INC | $4,141,000 | +21.7% | 1,020,000 | +27.7% | 3.26% | +48.5% |
| CUE | Buy | CUE BIOPHARMA INC | $4,122,000 | -44.1% | 1,655,477 | +9.6% | 3.25% | -31.8% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $3,809,000 | +18.1% | 276,802 | +36.2% | 3.00% | +44.1% |
| New | 1LIFE HEALTHCARE INCcall | $3,450,000 | – | 440,000 | +100.0% | 2.72% | – | |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $3,254,000 | – | 101,847 | +100.0% | 2.56% | – |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $3,143,000 | +93.1% | 161,527 | +118.5% | 2.48% | +135.7% |
| THC | New | TENET HEALTHCARE CORP | $2,665,000 | – | 50,700 | +100.0% | 2.10% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $1,869,000 | – | 176,680 | +100.0% | 1.47% | – |
| SBTX | Buy | SILVERBACK THERAPEUTICS INC | $1,446,000 | +26.6% | 341,108 | +4.8% | 1.14% | +54.5% |
| PRQR | Buy | PROQR THRAPEUTICS N V | $1,328,000 | +145.0% | 1,707,509 | +184.9% | 1.05% | +198.9% |
| ARDX | New | ARDELYX INC | $1,276,000 | – | 2,163,520 | +100.0% | 1.00% | – |
| INMD | Sell | INMODE LTD | $1,008,000 | -45.4% | 45,000 | -10.0% | 0.79% | -33.4% |
| APEN | New | APOLLO ENDOSURGERY INC | $329,000 | – | 90,176 | +100.0% | 0.26% | – |
| Sell | COGNITION THERAPEUTICS INC | $254,000 | -61.5% | 120,198 | -49.9% | 0.20% | -53.1% | |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -93,923 | -100.0% | -0.19% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.22% | – |
| SIOX | Exit | SIO GENE THERAPIES INC | $0 | – | -670,300 | -100.0% | -0.29% | – |
| Exit | ORGANON & COput | $0 | – | -20,000 | -100.0% | -0.45% | – | |
| NEO | Exit | NEOGENOMICS INC | $0 | – | -63,524 | -100.0% | -0.50% | – |
| GMED | Exit | GLOBUS MED INCcl a | $0 | – | -18,000 | -100.0% | -0.86% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -34,000 | -100.0% | -1.38% | – |
| SEM | Exit | SELECT MED HLDGS CORP | $0 | – | -90,788 | -100.0% | -1.41% | – |
| ACCD | Exit | ACCOLADE INC | $0 | – | -124,393 | -100.0% | -1.41% | – |
| OSCR | Exit | OSCAR HEALTH INCcl a | $0 | – | -237,500 | -100.0% | -1.53% | – |
| EHC | Exit | ENCOMPASS HEALTH CORP | $0 | – | -39,900 | -100.0% | -1.83% | – |
| QDEL | Exit | QUIDEL CORP | $0 | – | -25,675 | -100.0% | -1.86% | – |
| AGL | Exit | AGILON HEALTH INC | $0 | – | -140,000 | -100.0% | -2.29% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -22,704 | -100.0% | -2.39% | – |
| CNVY | Exit | CONVEY HEALTH SOLUTIONS HLDG | $0 | – | -748,134 | -100.0% | -3.16% | – |
| Exit | GALAPAGOS NVcall | $0 | – | -195,000 | -100.0% | -7.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.